PRESENTATIONS
“Empiricism and Bioethics: Can This Help Accelerate Transition of Candidate Genomics Applications to Practice?“. IUPHAR Workshop: “Implementation and obstacles of pharmacogenetics in clinical practice”. The 16th World Congress of Basic and Clinical Pharmacology WorldPharma2010, Copenhagen, Denmark, 2010.
“Science Policy and Knowledge Translation in the Post-genomics Era: A Proposal for an ‘Essential Diagnostics’ Library’.” Symposium: Bridging the Continents in Istanbul: Personalized & Predictive Medicine in Turkey - Too Soon or Just-in-Time? Yeditepe University, Istanbul, September 2009.
“Ethical issues in pharmacogenetics: Journey of personalized medicines from laboratory bench to bedside and the developing world marketplace”. World Congress of Pharmacy and Pharmaceutical Sciences. Istanbul. September 2009.
“Theragnostics and Essential Diagnostics Library.” World Health Organization, Department of Research Policy and Cooperation, Geneva. July 2009.
“Theragnostics in the Post-Genomics Era: Co-production of socio-technical evidence for regulation of diagnostic tests and pharmaceuticals?” CIHR Ethics and Regulation Workshop: Reassessing the Governance of Clinical Trials: Preventing Real World Risks at the Gate. Workshop funded by the “Situating Science: SSHRC Cluster for the Humanist and Social Studies of Science, Nova Scotia Health Research Foundation, and the Canadian Institutes of Health Research”, Halifax, Canada, March 2009.
“Race as a variable in pharmacogenomics science: From empirical ethics to publication standards”. XI São Paulo Research Conference on Molecular Medicine and Pharmacogenetics, jointly with IUPHAR. São Paulo, Brazil, September 2008.
“Fusion of Therapeutics and Diagnostics as ‘Theragnostics’ Unanticipated Impacts on Health”. International Sociological Association Research Committee on the Sociology of Health (RC15) & The Canadian Medical Sociology Association Inaugural Meeting Montréal, Canada, May 2008.
“Publication ethics in pharmacogenomics and personalized medicine”. Niigata University Research Grand Round Series, Niigata, Japan, April 2008.
“Shifting policy from ethnicity to human genome variation: Qualitative research on scientists’ perceptions”. International Congress in Pharmacogenetics and the Annual Meeting of the Pacific Rim Association for Clinical Pharmacogenetics, Busan, Korea, April 2008.
“Unpacking the silent heterogeneity and ethical issues in ‘-omics’ technologies: The case of proteomics and genomics”. Pharma Innovation in Canada 2008: The Future Landscape: New Technologies, Partnerships & Strategies for Success in a Highly-Competitive Global Market. Organized by INSIGHTINFO. The Old Mill, Toronto, Canada. January 2008.
“Mapping translational research in personalized therapeutics: From molecular markers to health policy”. Annual Congress of the German Association of Clinical Pharmacology, Kiel, Germany. November 2007.
“What is theragnostics and how will it change drug development, medical innovation and commercialization?” German Sepsis Society Annual Meeting - Symposium on “Theragnostics in Severe Infection”. Weimar, Germany. September 2007.
“Pharmacokinetic and pharmacodynamic integration in clinical pharmacogenetics of antipsychotic drugs”. Collegium Internationale Neuro-psychopharmacologicum (CINP) 25th Biennial Congress, Integrated Symposia on Pharmacogenomics and Customized Therapies in Psychiatry, Chicago, USA. July 2006.
“CYP2D6 genotype contributes to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity: CYP2D6-dopamine-serotonin crosstalk re-visited”. 13th Annual Meeting of the Pacific Rim Association for Clinical Pharmacogenetics (PRACP), International Congress on Pharmacogenetics, Satellite Meeting of the 15th World Congress of Pharmacology (IUPHAR-2006), Changsha, Hunan, China. June 2006.
“Personalized medicine and pharmacogenetics”. 6th International Congress of the Worldwide Hungarian Medical Academy, Semmelweis University, Budapest, Hungary. August 2005.
“Pharmacogenetics of prolactin response in Chinese healthy volunteers”. 12th Annual Meeting of the Pacific Rim Association for Clinical Pharmacogenetics, Kyoto, Japan. April 2005.
“Repeated Drug Administration (RDA) Studies can substitute twin studies in pharmacogenetics”. Statistical Genetics Seminar, Department of Genetics and Epidemiology, University of Toronto, Toronto, Canada, April 1999.
“Role of clonidine in heroin withdrawal”. Ontario Detox Directors’ Association Executive Meeting, Toronto, Canada, January 1992.